VaxigripTetra

VaxigripTetra

vaccine, influenza

Manufacturer:

sanofi pasteur

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Quadrivalent influenza vaccine (split virion, inactivated)
Indications/Uses
Active immunisation of adults & childn ≥6 mth for prevention of influenza disease caused by 2 influenza A virus subtypes & 2 influenza B virus types.
Dosage/Direction for Use
IM/SC Adult & childn 6 mth-17 yr 1 dose of 0.5 mL. Childn <9 yr who have not been previously vaccinated 2nd dose of 0.5 mL given after at least 4 wk interval.
Contraindications
Hypersensitivity to vaccine, eggs (ovalbumin, chicken proteins), neomycin, formaldehyde, octoxinol-9. Postpone vaccination in moderate or severe febrile or acute disease.
Special Precautions
Anaphylactic reaction. Not to be inj intravascularly. Thrombocytopaenia or bleeding disorder; syncope. Insufficient Ab response in patients w/ endogenous or iatrogenic immunosuppression. Interference w/ serological testing. Infants <6 mth.
Adverse Reactions
Headache; myalgia; malaise, shivering, fever, inj site pain, erythema, swelling & induration. Childn: Vomiting; irritability, lost appetite, abnormal crying, drowsiness, inj site tenderness. Inj site ecchymosis.
Drug Interactions
Reduced immunological response w/ immunosuppressant treatment. False +ve results in serology tests using ELISA method.
ATC Classification
J07BB02 - influenza, inactivated, split virus or surface antigen ; Belongs to the class of influenza viral vaccines.
Presentation/Packing
Form
VaxigripTetra vaccine 0.5 mL/dose
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in